Introduction
Dengue is an arbovirus that causes infection with any one of four related dengue viral serotypes. It is currently the most important mosquito-borne viral pathogen affecting humans, and it is emerging as a major threat to global health. (1) The best estimates available indicate that some 3 billion people live in parts of the world where they are at risk for infection and that approximately 40 million symptomatic episodes and approximately 20,000 deaths occur each year as a result of dengue. Currently, neither vaccines nor specific therapies are available for this disease, although both areas are currently the focus of intense research efforts. With expert supportive care, mortality rates have been reduced to very low levels, down to less than 1% in many centres of excellence for those with severe infections.(2) From 1968 until 2009, the World Health Organization (WHO) declared that Indonesia was the country with the highest rate of dengue haemorhagic fever (DHF) in Southeast Asia. (3) Dengue virus (DENV) has four serotypes: dengue (DEN)-1, DEN-2, DEN-3 and DEN-4, which target the liver, spleen, kidneys, lungs and bone marrow.(4) After being bitten by an infected mosquito, DENV enters the body and replicates within the mononuclear phagocytic cells (such as macrophages/monocytes). The incubation period of DENV infection is 7-10 days. The viraemic phase is followed by fever at which time the patient becomes infectious. This stage can be followed by a convalescent phase or progress to the plasma leakage phase that may cause DHF/dengue shock syndrome (DSS), that without proper treatment can be fatal. (1, 5) One of the central hypotheses proposed three decades ago for the pathogenesis of DHF/DSS was antibodydependent enhancement. Pre-existing antibodies to one serotype form immune complexes with heterotypic serotypes. These immune complexes bind to the FcγII (cluster of differentiation (CD)32) receptor (FcγIIR) on monocytes/macrophages that facilitates the entry, replication and spread of DENV, increasing the disease severity. (4) Dengue infection is divided into four grades of severity according to the WHO 2011 criteria. The presence of thrombocytopenia (<100,000 cells/mm 3 ) along with haemoconcentration (increased hematocrit (Hct) ≥20%) differentiates DHF from grades I and II of dengue fever (platelets <150,000 cells/mm 3 and increased Hct 5-10%), while circulatory failure is considered DHF grade III and severe shock indicates grade IV or DSS. (6) Monocytes and macrophages have long been suspected of being the primary target cells of DENV infection. A study by Kou, et al., The inclusion criteria were patients with dengue infection included fever (body temperature ≥38°C) for less than five days, and the IgM/IgG dengue/nonstructural protein 1 (NS1)/polymerase chain reaction (PCR) were positive, whereas the exclusion criteria were if the sampling was not feasible; if the data were incomplete; and if there were co-infection with other infectious diseases obtained by anamnesis, communication with clinicians and medical records. The inclusion criteria for the control group was a normal complete blood count (CBC) result, and the exclusion criteria was a history of rheumatoid arthritis.
This study used ethylene diamine tetra acetate (EDTA) blood and FcγIIR expression was determined in 24 hours after sampling because sample stability only 48 hours. Expression of monocytes with FcγIIR in whole blood was determined using monoclonal antibody CD32 fluorescein isothiocyanate (FITC) (Cat No. #552883), CD14 PE (Cat No. #562691) and CD45 PerCP (Cat No. #347464) with a BD FACS Calibur flow cytometry (BD Biosciences, San Jose, CA, USA) and Cell-Quest software (BD Biosciences). The calibration test of the flowcytometer was carried out prior to the examination of the sample material by using CaliBRITE beads FACS Comp (BD Bioscience). Coefficient of variance of intra-assay precision on the expression of FcγIIR monocyte was 3.41%.
The collected data were checked for completeness and accuracy, then coded and tabulated and inserted into the computer. The subject characteristic data were presented descriptively in the form of mean and standard intersection for continuous data, while the categorical data functions and may be associated with the variability of the immune response associated with the pathogenesis of dengue.(11) Earlier study showed that FcγIIR expression higher in secondary infection than primer. (12) Nowadays, there is no data about the level of FcγIIR expression in healthy individual. The objective of this study was to evaluate the expression of FcγIIR monocytes in patients with DENV infection and in healthy subjects.
were presented in the form of frequency and proportion. A mean test and proportion test between the characteristics of research subjects was performed.
Statistical analyses were performed using SPSS v.17.0 (SPSS Inc, Chicago, Illinois, USA). Continuous data were summarized using means for normally distributed data and median for abnormally distributed data. Ordinal and categorical data were summarized with ratios or proportions. Between-group differences were assessed using the MannWhitney test or independent T-test depend on normality. Statistical significance was considered if p<0.05.
This study was approved by Faculty of Medicine Universitas Gadjah Mada Ethical Commission Board with certificate number KE/FK/256/EC.
Results
Sixty-five subjects were included in this study, and among these 41 patients had dengue infection and 24 were healthy subjects. In the healthy subjects group, 11 participants (45.8%) were ≤ 15 years old and 13 participants (54.2%) were > 15 years; 12 participants (50%) were male and 12 participants (50%) were female. Among the patients in the dengue infection group, 18 participants (41.9%) were ≤15 years old were 23 participants (53.3%) were > 15 years old, also 22 participants (53.7%) were male and 19 participants (46.3%) were female (Table 1) .
Healthy Subjects n (%) Patient with Dengue Infection n (%)
≤15; x ± SD 8. CBC test showed that there is no significant differences in hemoglobin (Hb) and Hct values, but found significant differences in the numbers of leukocytes, the absolute number of monocytes, and platelet counts (p<0.001, 0.002 and <0.001, respectively) ( Table 2 ). There was a significant difference in FcγIIR expression on monocytes between healthy subjects and patients with dengue infection, p<0.0001 (Table 3) .
There were no cases of hematemesis/melena or shock in the patients in the dengue infection group. There was a significant difference of FcγIIR between groups in hepatomegaly vs. non-hepatomegaly and ascites vs. nonascites, p=0.005 and 0.031, respectively (Table 4) .
Of the forty-one patients with dengue infection, 26 people were diagnosed with dengue fever and 15 with DHF. There was no significant difference between the groups in the mean FcγIIR expression of the monocytes, Hb, number of leukocytes, the absolute number of monocytes and the day of fever. However, there was a significant difference in the increased value of the Hct and platelet counts (p=0.004 and 0.004, respectively) ( Table 5) .
There was no significant difference in the expression of FcγIIR on monocytes by age group and gender, but a significant differences in the day of fever (p=0.005) between the degue fever and DHF groups ( Table 6 ). The mean of monocyte's FcγIIR (CD32) expression was significantly different between days 3 and 4 of fever on post-hoc analysis (p=0.001). 
Discussion
Ribonucleic acid (RNA) of DENV has been isolated from the bone marrow in patients infected with DENV, indicating that the bone marrow and hematopoietic system were also the target of DENV. In addition, DENV was also recently isolated from polymorphonuclear neutrophil (PMN), monocytes/macrophages and dendritic cells. (13) Leukopenia and monocytopoenia in this study was similar with the study that that conducted by Kalayanarooj, et al., in Bangkok in children with a fever less than 72 hours, for whom neutropenia and monocytopoenia signified dengue infection vs. other fever illness. (14) Similar results were also obtained in a study from the Philippines in which 215 dengue patients had routine haematology checked on the fourth or fifth day of fever, which found 136 patients (63.3%) had leucopoenia. (15) Funahara, et al., proved that the DENV antigen can affect platelets directly without going through the immune responses.(16) A recent study conducted by Ghosh, et al., showed that DENV can directly interact and activate platelets. RNA and DENV particles had also been detected in platelets in patients infected with DENV, indicating that DENV was able to replicate in platelets by an unknown mechanism. (13) Hepatomegaly was more frequently found in patients with DHF compared to dengue fever. Hepatic dysfunction could occur due to the direct effects of the infection or because of an immune response. (17) (21) In contrast with this study's results that showed no significant differences in FcγIIR expression on monocytes between dengue fever vs. DHF groups, the expression of FcγIIR on monocytes in dengue patients was likely influenced by the patterns of viraemia and the kinetics of the immune response to dengue infection caused this study used subjects with various day of fever. Other study confirm that FcγIIR expression on monocytes was not related to clinical severity. Dengue infection is the result of a multifactorial interaction between agents, the host, and the environment.
On the one hand, the immune response can be beneficial, but it may also be detrimental, which prompted the interest of the authors interested in understanding the involvement of genetic factors in these infections, namely genetic susceptibility. 
Conclusion
The mean expression of FcγIIR (CD32) on monocytes in patients with dengue infection was higher than in healthy subjects. FcγIIR expression was not significantly different between dengue fever and DHF.
